Seeking Alpha
Long only, special situations, biotech, small-cap
Profile| Send Message|
( followers)  

In the second part of this article I wrote about three companies that are making some spectacular progress in their studies and some of them have also reached agreements on distribution of medical products.

There are another three companies that have promising studies against the cancer and cocaine addiction. So in this article I will write about the reasons to take a speculative position in Cellceutix Corporation (OTCQB:CTIX), Geron Corporation (NASDAQ:GERN) and Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX).

1. Cellceutix Corporation (OTCQB:CTIX)

Cellceutix Corporation, a development stage biopharmaceutical company, engages in the discovery and development of small molecule drugs to treat unmet medical conditions. The company’'s lead product candidate includes Kevetrin, which is in pre-clinical development stage primarily for the treatment of all cancers. It is also developing various other product candidates for the treatment of psoriasis, rheumatoid arthritis, osteo-arthritis/asthma, hypertensive emergency, and autism, as well as neurological disorders, such as multiple sclerosis, Lou Gehrig disease, and/or Parkinson's disease. Cellceutix Corporation has a collaborative agreement with Pioneer Valley Life Sciences Institute to investigate Kevetrin's role in antitumor activity in the context of age-related mitochondrial dysfunction.

Pipeline Portfolio


(Click to enlarge)

New catalyst

- On September 10, 2012, Cellceutix Corporation announced that it is in discussions with a major university (the "University") in Europe wishing to conduct clinical trials on Kevetrin, the Company's flagship anti-cancer compound. The University, which is ranked in the top ten of universities in Europe by review firm 4 International Colleges & Universities, wishes to test Kevetrin as a combination therapy for leukemia with drugs proprietary to one of the world's largest pharmaceutical companies.

Next catalyst

- Next Phase II of Keventrin.

- Next Phase II of Plurisol.

Fundamentals Analysis

Short interest


(Click to enlarge)


(Click to enlarge)

(SOURCE)

Analyst Research

Insufficient Information.

Financials

The company reported the first-quarter financial results on May 18 with the following highlights:

Revenue $0
Net Income $308k
Cash $93k

Chart Analysis


(Click to enlarge)

- Rsi is in a good position. The stock is in a bullish channel. The MACD marks an upward trend.

2. Geron Corporation (GERN)

It is a biopharmaceutical company, develops therapies for cancer. The company’s clinical development product candidates include Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of metastatic breast cancer, advanced non-small cell lung cancer, thrombocythemia, and myeloma; and GRN1005, a lipoprotein receptor-related protein-1 directed peptide-drug conjugate that is used to transport paclitaxel, an anti-cancer drug in the blood brain barrier.

Pipeline Portfolio


(Click to enlarge)

(SOURCE)

New Catalyst

-On September 10, 2012, Geron Corporation announced that, on the basis of an unplanned interim analysis, it is discontinuing its randomized Phase II study of imetelstat in metastatic HER2-negative breast cancer because median progression-free survival (PFS) in the imetelstat arm was shorter than in the comparator arm. The company also announced that it is continuing its randomized Phase II study of imetelstat in advanced non-small cell lung cancer (NSCLC). However, although a separate interim analysis of the NSCLC study suggested a modest trend of efficacy in favor of the imetelstat arm, the pre-specified success criteria in this trial are unlikely to be met, and, as a consequence, it is doubtful that Geron will take imetelstat forward into Phase III development for NSCLC.

Next Catalyst

- Clinical data of GRN1005 in breast cancer with metastases in the brain.

- Clinical data of GRN1005 in non-small cell lung cancer (NSCLC) with metastases in the brain.

Fundamentals Analysis

Short interest

Settlement Date Short Interest Avg Daily Share Volume Days To Cover
8/31/2012 6,854,932 1,837,927 3.729709
8/15/2012 6,738,538 447,396 15.061686
7/31/2012 7,078,525 693,032 10.213850
(SOURCE)

Analyst Research

(SOURCE)

Financials

The company reported the second-quarter financial results on August 3 with the following highlights:

Revenue $130k
Net Income ($18.32MM)
Cash $120.84MM

Chart Analysis


(Click to enlarge)

- Rsi is in a good position. The MACD marks a change of upward trend. The stock is in a bullish channel.

3. Catalyst Pharmaceuticals (CPRX)

It is a pharmaceutical company focused on the de­vel­opment and marketing of pre­scrip­tion drugs to fight against addictions, manage pain, and treat diseases of the central nervous system such as epilepsy. Catalyst is de­vel­op­ing vigabatrin, des­ig­nated CPP-109 by Catalyst for the treatment of addiction to cocaine, meth­am­phet­a­mine, and other addictive sub­stances. Catalyst is also de­vel­op­ing a more potent form of vigabatrin (des­ig­nated CPP-115 by Catalyst) to combat drug addiction - including opiate addiction in managing pain - and to treat central nervous system indications such as epilepsy.

For further information, please read my previous article on this issue.

Pipeline Portfolio


(Click to enlarge)

(SOURCE)

New Catalyst

- Catalyst Pharmaceutical has recently announced that it expects to report top-line results from its CPP-109 (vigabatrin) Phase II(b) trial around the end of September 2012 versus the previous guidance of early in the first quarter of 2013. This advancement on the presentation of results suggests that possible data will be very positive. In the following graph the estimates of potential consumers of CPP-109 in U.S. are shown.

Next Catalyst

- Top-line results from its CPP-109 (vigabatrin) Phase II(b) trial around the end of September 2012.

Fundamentals Analysis

Short interest

Settlement Date Short Interest Avg Daily Share Volume Days To Cover
8/31/2012 2,051,825 1,658,088 1.237464
8/15/2012 1,601,562 707,816 2.262681
7/31/2012 1,481,937 1,051,012 1.410010
(SOURCE)

Analyst Research

(SOURCE)

Financials

The company reported the second-quarter financial results on August 14 with the following highlights:

Revenue $0
Net Income

($289k)

Cash $7.51MM

Chart Analysis


(Click to enlarge)

- The MACD marks an upward trend. RSI is in a good position. The stock is in a bullish channel.

*Chart data sourced from stockcharts and shortanalytics.com, all other data sourced from Nasdaq.com and yahoo.com as well as the web of the previously mentioned company.

Source: 3 Best Biotech Stocks For This Week (Part III)